[Tamoxifen, endometrial cancer and levonorgestrel intra-uterine device].
作者信息
Espié M
机构信息
Centre des maladies du sein, hôpital Saint-Louis, Paris, France.
出版信息
Gynecol Obstet Fertil. 2003 Oct;31(10):867-71. doi: 10.1016/j.gyobfe.2003.07.006.
PMID:14642946
Abstract
Although the adjuvant tamoxifen benefit/risk rate is unquestionable in breast cancer treatment, the increase of endometrial cancer in chemoprevention is about to be a real problem. In the studies currently published metrorragia in the main signal. Levonogestrel intra-uterine device has not proved its efficacy for the decrease of this risk.
摘要
Zotero 插件